30,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Extracellular α-synuclein has been proposed as a crucial mechanism for induction of pathological aggregate formation in previously healthy cells. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
We have investigated the extent and pattern of immunostaining for ubiquitin protein (UBQ) in 60 patients with frontotemporal lobar degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U), 37 of whom were ascertained in Manchester UK and 23 in Newcastle-Upon-Tyne, UK. 1 key finding →
Participants: 60 Evidence: low
Full summary, score breakdown and related studies → Original source
In contrast to informal clinical evaluations of oculomotor dysfunction frequency (previous studies: 38%, current clinical examination: 33%), detailed eyetracking investigations revealed eye movement abnormalities in 80% of patients with posterior cortical atrophy (compared to 17% typical Alzheimer's disease, 5% controls). 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
In a convenience sample of deceased football players who donated their brains for research, a high proportion had neuropathological evidence of CTE, suggesting that CTE may be related to prior participation in football. 3 key findings →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source
The findings support the idea that gait and balance assessment may augment the diagnostic evaluation of dementia. 1 key finding →
Design: cross-sectional Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
p-Tau217 levels were highest in patients with Alzheimer's disease (AD) dementia, whereas NfL levels were highest in patients with frontotemporal dementia (FTD). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
NFL discriminated patients from controls with an area under the curve of 0.914 (95% CI, 0.843-0.984; p < 0.001) (cut-off: 76.46 pg/mL; 94% sensitivity, 76.9% specificity). 5 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
ANG levels didn't differ significantly between cases and controls. 3 key findings →
Participants: 88 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Type 2 diabetes is an established risk factor for dementia. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
All six CTE stage III cases had Braak NFT stage III but no neuritic plaques. 5 key findings →
Design: clinical trial Participants: 39 Evidence: low
Full summary, score breakdown and related studies → Original source
The neuropathology of Parkinson's disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. 2 key findings →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Three main recommendations are presented: (1) For AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are strongly recommended for improving cognition and daily function based on moderate evidence; (2) Cholinesterase inhibitors are conditionally recommended for vascular dementia and Parkinson's disease dementia, with a strong recommendation for Lewy body dementia; (3) For moderate to severe AD, NMDA receptor antagonist (memantine) is strongly recommended, demonstrating significant cognitive and functional improvements. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
The ability to perform activities of daily living (ADL) function is a multifaceted construct that reflects functionality in different daily life situations. 2 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
Highly educated at-risk subjects had better cognition and higher grey matter volume at baseline; moreover, higher educational attainment was associated with slower loss of grey matter over time in mutation carriers. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among the compounds detected in greater abundance in the CSF of patients with DLB compared with patients with AD, only one had a xenobiotic profile potentially related to the pathophysiology of DLB. 5 key findings →
Participants: 45 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Age of acquisition of nouns (p = 0.034, |d| = 0.77) and lexical density (p = 0.0064, |d| = 0.72) were reduced in SYN + AD, and together showed excellent discrimination for SYN + AD vs. SYN-AD (95% sensitivity, 66% specificity; AUC = 0.82). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Individuals with DLB (n = 50) died 3.24 ± 1.81 years after diagnosis, typically of disease-related complications. 5 key findings →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegeneration in Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) affect cortical and subcortical networks involved in saccade generation. 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Both variants of FTD showed significant increases in rates of elation, disinhibition, and aberrant motor behavior compared with AD. 5 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source
The final cohort comprised 52 patients, 30 of whom met basic PPA criteria. 5 key findings →
Participants: 52 Evidence: moderate
Full summary, score breakdown and related studies → Original source
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Linear models showed that plasma GFAP was significantly higher in αSyn+AD compared to αSyn (β = 0.31, 95% CI = 0.065-0.56, and P = 0.015), after covarying for age at plasma, plasma-to-death interval, and sex; plasma p-tau 181 was not (P = 0.37). 4 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the primary type of dementia, followed by frontotemporal lobar degeneration (FTLD). 1 key finding →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 2,748 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,180 records, built mostly from automated pulls of Europe PMC (64.2% of the library) and OpenAlex (16.9%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →